Abstract:Most therapeutic peptides available on the market today are naturally occurring hormones or protein fragments that were serendipitously discovered to possess therapeutic effects. However, the limited repertoire of available natural resources presents difficulties for the development of new peptide drug candidates. Traditional peptides possess several shortcomings that must be addressed for biomedical applications, including relatively low affinity or specificity toward biological targets compared to antibody- and protein scaffold-based affinity molecules, poor in vivo stability owing to rapid enzymatic degradation, and rapid clearance from circulation owing to their small size. Going forward, it will be increasingly important for scientists to develop novel classes of high-affinity and -specificity peptides against desired targets that mitigate these limitations while remaining compatible with pharmaceutical manufacturing processes. Recently, several highly constrained, artificial cyclic peptides have emerged as platforms capable of generating high-affinity peptide binders against various disease-associated protein targets by combining with phage or mRNA display method, some of which have entered clinical trials. In contrast, although linear peptides are relatively easy to synthesize cost-effectively and modify site-specifically at either N- or C-termini compared to cyclic peptides, there have been few linear peptide-based platforms that can provide high-affinity and -specificity peptide binders.In this Account, we describe the creation and development of a novel class of high-affinity peptides, termed "aptide"-from the Latin word "aptus" meaning "to fit" and "peptide"-and summarize their biomedical applications. In the first part, we consider the design and creation of aptides, with a focus on their unique structural features and binding mode, and address screening and identification of target protein-specific aptides. We also discuss advantages of the aptide platform over ordinary linear peptides lacking preorganized structures in terms of the affinity and specificity of identified peptide binders against target molecules. In the second part, we describe the potential biomedical applications of various target-specific aptides, ranging from imaging and therapy to theranostics, according to the types of aptides and diseases. We show that certain aptides can not only bind to a target protein but also inhibit its biological function, thereby showing potential as therapeutics per se. Further, aptides specific for cancer-associated protein antigens can be used as escort molecules or targeting ligands for delivery of chemotherapeutics, cytokine proteins, and nanomedicines, such as liposomes and magnetic particles, to tumors, thereby substantially improving therapeutic effects. Finally, we present a strategy capable of overcoming the critical issue of short blood circulation time associated with most peptides by constructing a hybrid system between an aptide and a hapten cotinine-specific antibody.

Peptide-based inhibitors of epigenetic proteins

Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors

Cyclic peptides target the aromatic cage of a PHD-finger reader domain to modulate epigenetic protein function

Leveraging a Phage-Encoded Noncanonical Amino Acid: A Novel Pathway to Potent and Selective Epigenetic Reader Protein Inhibitors

Peptides as drugs: from screening to application

Synthetic peptides: promising modalities for the targeting of disease related nucleic acids

Epigenetics-targeted drugs: current paradigms and future challenges

Epigenetic Modulators as Therapeutic Agents in Cancer

Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development

Covalent inhibitors meet epigenetics: New opportunities

DNA methyltransferase inhibitors: an updated patent review (2012-2015)

Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies

CHAPTER 7. Targeting Non-Acetylation Histone Erasers

The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

A Computational Approach for the Discovery of Novel DNA Methyltransferase Inhibitors

Discovery of cysteine-targeting covalent histone methyltransferase inhibitors

Mimicking the Nucleosomal Context in Peptide-Based Binders of a H3K36me Reader Increases Binding Affinity While Altering the Binding Mode

Peptide Regulation of Gene Expression: A Systematic Review

Biomedical Applications of a Novel Class of High-Affinity Peptides

Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy